Interventions of Interest The independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic therapies; suzetrigine has potential to be cost-saving due to avoided future cases of opioid use disorder. Final Documents For questions please contact [email protected]. View the Key Stakeholder List. ICER’s Chief Medical Officer David Rind, MD […]
Interventions of Interest: ICER developed a report assessing the comparative clinical effectiveness and value of certain non-pharmacologic, non-invasive interventions for chronic low back and neck pain. The report was the subject of a October 19, 2017 meeting of the California Technology Assessment Forum. Evidence from the report suggested safe and effective treatments include acupuncture, cognitive […]
Interventions of interest: Erenumab (Aimovig®, Amgen/Novartis) Fremanezumab (Ajovy®, Teva) Galcanezumab (Emgality®, Eli Lilly) Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or […]